Therefore, expression of BAK1 may play some role in Barrett’s patients by conferring resistance to potential cancer cells by regulating cytochrome c oxidase and mitochondrial energy metabolism, known to be differentially altered across the normal-metaplasia-dysplasia-adenocarcinoma disease sequence in Barrett’s esophagus [9]. The gene discussed is BAK1; the disease is esophageal adenocarcinoma.